Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

Treating Clots and Managing Your Long-Term Risk

At a Glance

Protein C deficiency raises the risk of venous blood clots, but the diagnosis alone does not require lifelong blood thinners. Treatment depends on clot history, whether a trigger was present, recurrence and bleeding risks, kidney function, pregnancy, and personal preferences.

Treatment for Protein C deficiency is rarely about “fixing” the deficiency itself. Instead, it focuses on managing your risk of blood clots. Because the risk of clotting varies significantly from person to person, your treatment plan will be tailored to your specific history and life circumstances [1][2].

Managing an Active Blood Clot

If you develop a venous thromboembolism (VTE), such as a DVT or PE, the immediate goal is to stop the clot from growing.

  • DOACs (Direct Oral Anticoagulants): Many nonpregnant adults without contraindications can receive apixaban (Eliquis) or rivaroxaban (Xarelto) as initial treatment without an injectable lead-in [3]. While robust data in well-characterized natural-anticoagulant deficiencies specifically remains limited, observational evidence supports DOACs as a reasonable and effective option [4][5].
  • Injectable Heparins (LMWH or UFH): Fast-acting injectable blood thinners, like low-molecular-weight heparin (LMWH) or unfractionated heparin, are selected for particular situations such as pregnancy, severe renal impairment, or other individualized circumstances [6][7].
  • Warfarin (Coumadin): This is a traditional option, but it requires special care in Protein C deficiency. Because warfarin temporarily lowers Protein C even further when you first start it, you must overlap (bridge) the warfarin with a rapidly acting injectable anticoagulant (like heparin) for at least five days and until your INR is therapeutic according to the prescriber. Failing to do this can lead to a rare but serious complication called warfarin-induced skin necrosis [8][9].

How Long Will You Need Treatment?

The duration of your treatment depends on the “why” behind your clot. Doctors look at whether a clot was provoked or unprovoked [1].

  1. Provoked Clots: If your clot was caused by a major, temporary trigger—such as major surgery, severe physical trauma, or being bedridden in a hospital—the standard course is often 3 to 6 months of treatment, as the risk drops significantly once the trigger is gone [10][11].
  2. Unprovoked or Recurrent Clots: If a clot happens “out of the blue” or if you have recurrent clots, your risk of a second clot is higher. In these situations, your doctor may recommend extended treatment [12][13].

However, Protein C deficiency alone does not mandate indefinite anticoagulation. An asymptomatic carrier is not ordinarily placed on lifelong anticoagulation solely because of the laboratory or genetic result. Deciding on extended treatment is a shared decision that balances your recurrence risk against your bleeding risk [14]. Tools like the VTE-BLEED score can help estimate bleeding risk, but the decision ultimately relies on clinical factors, kidney function, and your personal preferences [15][16].

Anticoagulant Safety Checklist

If you are prescribed an anticoagulant, you must follow strict safety guidelines:

  • Never stop or change your dose without direct medical advice.
  • Missed Doses: Ask your doctor exactly what to do if you miss a dose.
  • Drug Interactions: Avoid NSAIDs (like ibuprofen, naproxen) and aspirin unless explicitly prescribed, as they significantly increase bleeding risk.
  • Medical Alert: Wear a medical alert bracelet and disclose your medication to all dental and surgical teams.
  • Bleeding Red Flags: Seek immediate emergency care for signs of major bleeding: black or tarry stools, vomiting blood, severe headache, or any significant head injury.

Staying Safe in Daily Life

Even if you aren’t on daily blood thinners, you can take concrete steps to lower your risk during high-risk times:

  • Movement and Travel: During flights or car rides longer than 4 hours, stand up and walk every hour. If you cannot get up, perform “ankle pumps” (flexing your feet up and down) to keep blood moving in your calves. (Individualized travel planning and movement are essential) [17][18].
  • Surgical Planning: Always tell your surgeon and anesthesiologist about your Protein C deficiency. Perioperative prophylaxis depends on the procedure, bleeding risk, personal VTE history, and local protocol. Anticoagulants are not automatically given before surgery (which could increase bleeding), and mechanical methods or early ambulation may be appropriate instead [19][20].
  • Medication Awareness: Discuss the risks of estrogen-containing medications with your doctor, as these can significantly increase clotting risk in people with this mutation [21].

Consistency is key. Taking your medication exactly as prescribed is the most important thing you can do to prevent a recurrence [17].

Common questions in this guide

What blood thinner may be used for a clot in someone with Protein C deficiency?
Treatment commonly uses an anticoagulant, also called a blood thinner. Many nonpregnant adults without contraindications may receive apixaban or rivaroxaban, while injectable heparin may be preferred during pregnancy, with severe kidney impairment, or in other individualized situations. The safest choice depends on your medical history and bleeding risk.
How long might I need anticoagulation after a blood clot?
A clot linked to a major, temporary trigger such as surgery or hospitalization is often treated for 3 to 6 months. A clot without a clear trigger or repeated clots may lead to a discussion about longer treatment. Protein C deficiency alone does not automatically mean that anticoagulation must continue for life.
Why does warfarin need to be overlapped with heparin in Protein C deficiency?
Warfarin temporarily lowers Protein C when treatment begins, which can create a short-term increase in clotting tendency. A fast-acting injectable anticoagulant is therefore used alongside warfarin for at least five days and until the INR is therapeutic as directed by the prescriber. This reduces the risk of the rare but serious complication called warfarin-induced skin necrosis.
Does everyone with Protein C deficiency need lifelong blood thinners?
No. People who carry Protein C deficiency but have never had a clot are not usually placed on lifelong anticoagulation solely because of the laboratory or genetic finding. The decision after a clot balances the chance of another clot against the risk of serious bleeding, along with kidney function and personal preferences.
How can I lower my clot risk during travel or before surgery?
During flights or car trips longer than four hours, walk about once an hour when possible or do repeated ankle pumps while seated. Tell your surgeon and anesthesiologist about Protein C deficiency and any anticoagulant you take before a procedure. Medication or mechanical prevention is individualized because anticoagulants can also increase bleeding.
What bleeding symptoms need emergency attention while I take an anticoagulant?
Seek emergency care for black or tarry stools, vomiting blood, a severe headache, or any significant head injury. Do not stop or change your anticoagulant dose on your own; contact your medical team for instructions about missed doses or other concerns.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my blood clot 'provoked' by a specific event or 'unprovoked,' and how does that change how long I need to be on blood thinners?
  2. 2.Since I have Protein C deficiency, what is the safest way for me to start or stop warfarin if that is the drug we choose?
  3. 3.Is a DOAC (like Eliquis or Xarelto) appropriate for my specific mutation, or would you recommend a traditional option like warfarin?
  4. 4.What is my estimated risk of a major bleeding event versus my risk of having another clot?
  5. 5.If I am not on daily medication, what specific steps should I take during high-risk times like long flights or minor surgeries?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?

    Weitz JI, Prandoni P, Verhamme P

    TH open : companion journal to thrombosis and haemostasis 2020; (4(4)):e446-e456 doi:10.1055/s-0040-1721735.

    PMID: 33376944
  2. 2

    Genotype-Phenotype Relationships in a Large French Cohort of Subjects with Inherited Protein C Deficiency.

    Alhenc-Gelas M, Plu-Bureau G, Mauge L, et al.

    Thrombosis and haemostasis 2020; (120(9)):1270-1281 doi:10.1055/s-0040-1714100.

    PMID: 32717757
  3. 3

    Thrombophilia Screening: Not So Straightforward.

    Moore GW

    Seminars in thrombosis and hemostasis 2024; (50(8)):1131-1152 doi:10.1055/s-0044-1786807.

    PMID: 38733983
  4. 4

    Direct Oral Anticoagulants in Patients with Thrombophilia: Challenges in Diagnostic Evaluation and Treatment.

    Undas A, Góralczyk T

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2016; (25(6)):1321-1330 doi:10.17219/acem/65853.

    PMID: 28028988
  5. 5

    Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry.

    Cohen O, Kenet G, Levy-Mendelovich S, et al.

    Journal of thrombosis and thrombolysis 2024; (57(4)):710-720 doi:10.1007/s11239-024-02957-4.

    PMID: 38491267
  6. 6

    Should direct oral anticoagulants be used to treat protein C or S deficiency?

    Bennett KK, Schwier NC

    JAAPA : official journal of the American Academy of Physician Assistants 2023; (36(7)):8-10 doi:10.1097/01.JAA.0000937288.04720.58.

    PMID: 37368848
  7. 7

    Inherited Thrombophilia in the Era of Direct Oral Anticoagulants.

    Khider L, Gendron N, Mauge L

    International journal of molecular sciences 2022; (23(3)) doi:10.3390/ijms23031821.

    PMID: 35163742
  8. 8

    Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.

    Yamazaki H, Yagi S, Torii Y, et al.

    Journal of cardiology 2018; (71(3)):305-309 doi:10.1016/j.jjcc.2017.09.009.

    PMID: 29100817
  9. 9

    Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report.

    Kamada M, Kenzaka T

    World journal of clinical cases 2019; (7(24)):4285-4291 doi:10.12998/wjcc.v7.i24.4285.

    PMID: 31911909
  10. 10

    Deep vein thrombosis and pulmonary embolism.

    Di Nisio M, van Es N, Büller HR

    Lancet (London, England) 2016; (388(10063)):3060-3073 doi:10.1016/S0140-6736(16)30514-1.

    PMID: 27375038
  11. 11

    Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

    Áinle FN, Kevane B

    Blood advances 2020; (4(21)):5595-5606 doi:10.1182/bloodadvances.2020002268.

    PMID: 33170937
  12. 12

    Whole-exome sequencing identifies rare variants in STAB2 associated with venous thromboembolic disease.

    Desch KC, Ozel AB, Halvorsen M, et al.

    Blood 2020; (136(5)):533-541 doi:10.1182/blood.2019004161.

    PMID: 32457982
  13. 13

    Severe Multisystem Thrombotic Phenotype Associated With Protein C Deficiency in A Young Woman: A Case Report.

    Alif AA, Azad MAK, Kundu T, et al.

    Clinical case reports 2026; (14()):e72706 doi:10.1002/ccr3.72706.

    PMID: 42125170
  14. 14

    Basics of diagnosis and treatment of venous thromboembolism.

    Cox C, Roberts LN

    Journal of thrombosis and haemostasis : JTH 2025; (23(4)):1185-1202 doi:10.1016/j.jtha.2025.01.009.

    PMID: 39938684
  15. 15

    External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.

    Klok FA, Barco S, Konstantinides SV

    Thrombosis and haemostasis 2017; (117(6)):1164-1170 doi:10.1160/TH16-10-0810.

    PMID: 28276566
  16. 16

    Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.

    Klok FA, Barco S, Turpie AGG, et al.

    British journal of haematology 2018; (183(3)):457-465 doi:10.1111/bjh.15533.

    PMID: 30123981
  17. 17

    Non-vitamin K antagonist oral anticoagulants in patients with severe inherited thrombophilia: a series of 33 patients.

    Undas A, Goralczyk T

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(6)):438-442 doi:10.1097/MBC.0000000000000613.

    PMID: 28079536
  18. 18

    Analysis of PROC mutations and clinical features in 22 unrelated families with inherited protein C deficiency.

    Xu F, Zhang K, Xu Q, et al.

    Annals of hematology 2024; (103(2)):645-652 doi:10.1007/s00277-023-05487-w.

    PMID: 37950050
  19. 19

    Perioperative management of severe congenital protein C deficiency.

    Watanabe K, Kato M, Ishimaru T, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(8)):646-649 doi:10.1097/MBC.0000000000000654.

    PMID: 28737523
  20. 20

    Esophagectomy for Esophageal Cancer in a Patient with Protein C Deficiency: A Case Report.

    Ujiie N, Taniyama Y, Okamoto H, et al.

    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 2020; (26(5)):286-289 doi:10.5761/atcs.cr.20-00129.

    PMID: 32814726
  21. 21

    American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.

    Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al.

    Blood advances 2023; (7(22)):7101-7138 doi:10.1182/bloodadvances.2023010177.

    PMID: 37195076

This page is for informational purposes only and does not constitute medical advice. Your hematologist or prescribing clinician should tailor anticoagulant choice, duration, and travel or surgical plans to your clotting and bleeding risks.

Get notified when new evidence is published on thrombophilia due to protein C deficiency, autosomal dominant.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.